A groundbreaking study conducted by physician-scientists at the Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, has unveiled a fascinating molecular mimicry between the widely prescribed diabetes drug metformin and the biological effects of exercise in men undergoing treatment for prostate cancer. This investigation reveals that metformin elevates levels of N-lactoyl-phenylalanine (Lac-Phe), a metabolite intimately linked to energy balance and weight regulation, offering promising insights into how metabolic health can be supported during cancer care—even when patients are physically inactive.
Exercise has long been recognized as a cornerstone of supportive cancer therapy. Its multifaceted benefits, including regulation of body weight, blood glucose levels, and cardiovascular health, play a crucial role in determining patient well-being during and after treatment. Yet, intense fatigue, adverse effects from hormone therapy, pain, and disease progression often render sustained physical activity challenging or even impossible for many prostate cancer patients. Addressing this clinical void, researchers have sought alternative strategies that could elicit the favorable metabolic adaptations traditionally associated with exercise.
Central to this inquiry is Lac-Phe, a metabolite generated when lactate—accumulated during muscle exertion—combines with the amino acid phenylalanine. The presence of elevated Lac-Phe has been documented post-exercise, correlating with reduced appetite and enhanced weight control, hallmarks of healthy metabolism often observed in physically active individuals. Intriguingly, this study observed that metformin administration also raises Lac-Phe levels to comparable degrees, independent of physical activity. This pharmacological mimicry hints at an unexplored avenue whereby drug-induced metabolic signals might replicate some systemic benefits of exercise.
The Sylvester team focused their investigation on prostate cancer patients undergoing hormone therapy, a group known to face significant metabolic disturbances including weight gain, insulin resistance, and heightened cardiovascular risks. Blood sampling from these patients demonstrated that metformin treatment led to Lac-Phe elevations similar to those previously seen after strenuous exercise. Strikingly, these increases persisted despite the patients’ limited physical activity and ongoing hormone-based treatments, suggesting that metformin may alleviate metabolic strain through pathways analogous to those activated by exercise.
Notably, while Lac-Phe concentrations correlated strongly with metabolic health indices such as weight modulation, they did not align with traditional measures of cancer progression like prostate-specific antigen (PSA) levels. This distinction underscores the metabolite’s role as an indicator of systemic metabolic adaptation rather than direct anti-tumor efficacy. The findings therefore expand the conceptual framework of cancer care beyond tumor targeting to encompass holistic support for patient metabolic resilience, a factor increasingly recognized as vital to treatment tolerance and quality of life.
Further analysis revealed that Lac-Phe was not uniquely elevated by metformin but also increased in patients undergoing other metabolic therapies, suggesting its function as a broader biomarker of metabolic engagement rather than a drug-specific phenomenon. This universality enhances the clinical relevance of Lac-Phe as a potential marker to guide therapeutic strategies aimed at mitigating metabolic dysfunction during cancer treatment.
Comparative investigations distinguished Lac-Phe’s metabolic associations from those of GDF-15, a stress hormone previously linked to metformin use. While GDF-15 elevation following metformin administration does not correlate with weight changes, Lac-Phe demonstrates a tighter connection to body weight dynamics. This divergence implies that metformin employs multiple biochemical pathways to exert its overall metabolic influence, with Lac-Phe likely playing a pivotal role in the anti-obesity effects observed in these patients.
The implications of these discoveries are profound. By delineating how metformin engages molecular circuits typically triggered by physical exercise, this study paves the way for potential therapeutic innovations targeting metabolic health in prostate cancer patients unable to maintain sufficient physical activity. The ability to pharmacologically mimic exercise’s metabolic benefits could diminish treatment-related fatigue and weight gain, improve cardiovascular profiles, and ultimately enhance patient outcomes.
Senior investigators emphasize the power of integrating laboratory science, metabolic biology, and clinical oncology to achieve such insights. Their transdisciplinary approach exemplifies how collaboration across specialized programs—Tumor Biology, Cancer Epigenetics, and Translational & Clinical Oncology—can unravel complex biological questions with direct clinical relevance. Although further expansive research is warranted, these findings mark a significant advance in understanding the interplay between cancer therapies, metabolism, and patient well-being.
Metformin’s role extends beyond glucose-lowering effects to encompass diverse metabolic adaptations, influencing phenomena at cellular and systemic levels. As metabolism governs virtually all cellular activities, elucidating how commonly used drugs modulate these processes is key to optimizing therapeutic regimens in cancer care. The elevation of Lac-Phe by metformin highlights a previously underappreciated link between pharmacology and exercise physiology that could reshape supportive treatment paradigms.
Beyond the molecular data, the study resonates with a patient-centered perspective, reiterating that effective cancer treatment must prioritize not just tumor control but also maintenance of strength, resilience, and quality of life. Metabolic health emerges as a crucial target in this holistic approach, with Lac-Phe serving as a promising biomarker and potential therapeutic focal point. This insight encourages the oncology community to embrace multidimensional strategies that address the full spectrum of patient needs during the rigors of cancer therapy.
Looking forward, the research community anticipates expanding investigations into the mechanistic roles of Lac-Phe and related metabolites in cancer and metabolic diseases. Unraveling these pathways may unlock novel drug targets capable of replicating or augmenting beneficial exercise-induced signals. Ultimately, such work holds promise for transforming the landscape of cancer treatment, enabling interventions that sustain patient vigor and metabolic equilibrium throughout the continuum of care.
This landmark study’s publication in EMBO Molecular Medicine underscores its significance and underscores the momentum toward integrating metabolic biology into oncology. For patients with prostate cancer, it introduces a hopeful prospect that a well-established medication like metformin can be harnessed not only to control disease but also to nurture metabolic health, especially when exercise is limited. As precision medicine evolves, recognizing and therapeutically exploiting such metabolic interconnections will be essential to advancing personalized, comprehensive cancer care.
Subject of Research: Metabolic effects of metformin in prostate cancer patients; interaction of Lac-Phe metabolite with metabolic health during hormone therapy.
Article Title: The anti-obesogenic metabolite, Lac-Phe, is elevated by metformin treatment in prostate cancer patients
News Publication Date: 6-Apr-2026
Web References: http://dx.doi.org/10.1038/s44321-026-00408-6
Image Credits: Sylvester Comprehensive Cancer Center
Keywords: Prostate cancer, metformin, Lac-Phe, metabolism, hormone therapy, cancer treatment, metabolic health, exercise mimicry, energy balance, weight control, cancer supportive care, molecular oncology
